Comparative Pharmacology
Head-to-head clinical analysis: MACRILEN versus XYLOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACRILEN versus XYLOSE.
MACRILEN vs XYLOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MACRILEN (macimorelin) is a synthetic growth hormone secretagogue receptor (GHS-R) agonist that stimulates growth hormone (GH) release from the anterior pituitary. It mimics the action of ghrelin, enhancing GH secretion through GHS-R activation.
Xylose is a pentose sugar that is absorbed in the small intestine via passive diffusion and active transport. It is used to assess intestinal mucosal integrity; its absorption reflects the function of the enterocytes. After absorption, it is not metabolized and is excreted unchanged in urine, making it a marker for intestinal absorption and renal function.
1 mg subcutaneously once daily, titrated as needed to a maximum of 2 mg daily.
Adults: 25 g orally in 500 mL water, administered as a single dose for D-xylose absorption test.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours (range 2.5–4.5 hours) in healthy adults. This short half-life supports its use for diagnostic testing, with rapid clearance after stimulation of growth hormone release.
Terminal elimination half-life: 1.2-2.5 hours in adults with normal renal function; prolonged in renal impairment (up to 10 hours).
Primarily renal; approximately 90% of the administered dose is excreted unchanged in urine within 24 hours. Less than 5% is metabolized, with metabolites also eliminated renally. Fecal excretion is negligible (<2%).
Renal: approximately 85-90% eliminated unchanged in urine; biliary/fecal: negligible (<5%).
Category C
Category C
Diagnostic Agent
Diagnostic Agent